Laura Carter

12.7k total citations · 3 hit papers
45 papers, 7.7k citations indexed

About

Laura Carter is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Laura Carter has authored 45 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Immunology, 22 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Laura Carter's work include Immune Cell Function and Interaction (16 papers), Cancer Immunotherapy and Biomarkers (15 papers) and T-cell and B-cell Immunology (15 papers). Laura Carter is often cited by papers focused on Immune Cell Function and Interaction (16 papers), Cancer Immunotherapy and Biomarkers (15 papers) and T-cell and B-cell Immunology (15 papers). Laura Carter collaborates with scholars based in United States, Japan and United Kingdom. Laura Carter's co-authors include Beatriz M. Carreno, Lori Fitz, Clive R. Wood, Mary Collins, Tasuku Honjo, Lynette A. Fouser, Hiroyuki Nishimura, Yoshiko Iwai, Taku Okazaki and Michael Bowman and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Laura Carter

43 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

2000 4.2k citations Andrew J. Long, Yoshiko Iwai et al. The Journal of Experimental Medicine profile →
PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ

2004 631 citations Kelly-Ann Sheppard, Lori Fitz et al. FEBS Letters profile →
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2

2002 548 citations Laura Carter, Lynette A. Fouser et al. European Journal of Immunology profile →

Peers

Laura Carter

IMMUN

ONCOL

PRM

EPIDE

Michael Yellin United States

Loise M. Francisco United States

Clive R. Wood United States

Heidi F. Horton United States

Kristen E. Pauken United States

Allen T. Bruce United States

Vincent Ling United States

Tullia C. Bruno United States

Terri McClanahan United States

Yoshiko Iwai Japan

Michael Yellin United States

Laura Carter

5.2k ×1.0

IMMUN

4.7k ×1.1

ONCOL

1.6k ×1.4

543 ×0.8

PRM

551 ×1.1

EPIDE

Citations per year, relative to Laura Carter Laura Carter (= 1×) peers Michael Yellin

Countries citing papers authored by Laura Carter

Since Specialization

Citations

This map shows the geographic impact of Laura Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Carter more than expected).

Fields of papers citing papers by Laura Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Carter. The network helps show where Laura Carter may publish in the future.

Co-authorship network of co-authors of Laura Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Carter. A scholar is included among the top collaborators of Laura Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Carter. Laura Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pullamsetti, Soni Savai, Ravikumar Sitapara, Robin Osterhout, et al.. (2023). Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 24(16). 12653–12653. 11 indexed citations

Liu, Xiuting, Graham D. Hogg, Chong Zuo, et al.. (2023). Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell. 41(6). 1073–1090.e12. 53 indexed citations

Galkin, Anna, Ravikumar Sitapara, Bryan Clemons, et al.. (2022). Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. European Respiratory Journal. 60(6). 2102356–2102356. 49 indexed citations

Mahalingam, Devalingam, Judy S. Wang, Erika Hamilton, et al.. (2019). Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research. 25(12). 3508–3516. 47 indexed citations

Liu, Xikui, Hongxiu Li, Charles A. Lesch, et al.. (2019). RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment. Cancer Immunology Research. 7(7). 1054–1063. 11 indexed citations

Hu, Xiao, Kinga Majchrzak, Xikui Liu, et al.. (2018). In Vitro Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness In Vivo. Cancer Research. 78(14). 3888–3898. 42 indexed citations

Hu, Xiao, Yahong Wang, Ling-Yang Hao, et al.. (2015). Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists. Nature Chemical Biology. 11(2). 141–147. 176 indexed citations

Shin, Yoo Seob, Katsuyuki Takeda, Yoshiki Shiraishi, et al.. (2011). Inhibition of Pim1 Kinase Activation Attenuates Allergen-Induced Airway Hyperresponsiveness and Inflammation. American Journal of Respiratory Cell and Molecular Biology. 46(4). 488–497. 34 indexed citations

Robinson, John, et al.. (2011). The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease. Cellular Immunology. 272(2). 200–213. 38 indexed citations

10.

Wright, Dale, Stefan Groß, John Robinson, et al.. (2009). Inhibition of T cell function in vitro and in vivo using small molecule antagonists of PIM kinases (35.33). The Journal of Immunology. 182(Supplement_1). 35.33–35.33. 1 indexed citations

11.

Bedard, Patricia W., Valérie Clerin, Boris Tchernychev, et al.. (2007). Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis. Journal of Pharmacology and Experimental Therapeutics. 324(2). 497–506. 38 indexed citations

12.

Carter, Laura, Michael W. Leach, Mihai L. Azoitei, et al.. (2006). PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 182(1-2). 124–134. 156 indexed citations

13.

Sheppard, Kelly-Ann, Lori Fitz, Judith A. St. George, et al.. (2004). PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Letters. 574(1-3). 37–41. 631 indexed citations breakdown →

14.

Blazar, Bruce R., Beatriz M. Carreno, Angela Panoskaltsis‐Mortari, et al.. (2003). Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism. The Journal of Immunology. 171(3). 1272–1277. 267 indexed citations

15.

Carter, Laura & Beatriz M. Carreno. (2003). Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation. Immunologic Research. 28(1). 49–60. 28 indexed citations

16.

Kasaian, Marion T., Matthew J. Whitters, Laura Carter, et al.. (2002). IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation. Immunity. 16(4). 559–569. 400 indexed citations

17.

Carter, Laura, Lynette A. Fouser, Jason Jussif, et al.. (2002). PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. European Journal of Immunology. 32(3). 634–634. 548 indexed citations breakdown →

18.

Long, Andrew J., Yoshiko Iwai, Tatyana Chernova, et al.. (2000). Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. The Journal of Experimental Medicine. 192(7). 1027–1034. 4158 indexed citations breakdown →

19.

Carter, Laura, Xiaohong Zhang, Caroline Dubey, et al.. (1998). Regulation of T Cell Subsets from Naive to Memory. Journal of Immunotherapy. 21(3). 181–187. 55 indexed citations

20.

Carter, Laura & Susan L. Swain. (1997). Single cell analyses of cytokine production. Current Opinion in Immunology. 9(2). 177–182. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact